Search

Your search keyword '"Olinvyk (Medication)"' showing total 31 results
Start Over Descriptor "Olinvyk (Medication)" Topic pharmaceutical industry
31 results on '"Olinvyk (Medication)"'

1. Trevena Reports First Quarter 2024 Results and Provides Business Update

Subjects
Trevena Inc., Pharmaceutical industry, Olinvyk (Medication)
Abstract

ENPNewswire-May 16, 2024--Trevena Reports First Quarter 2024 Results and Provides Business Update (C)2024 ENPublishing - http://www.enpublishing.co.uk Release date- 15052024 - CHESTERBROOK - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused [...]

Published
2024

2. Trevena Inc Business Update - Final

Subjects
Trevena Inc., Chief financial officers, Pharmaceutical industry, Business, Olinvyk (Medication)
Abstract

Presentation OPERATOR: Greetings, and welcome to the Trevena corporate update. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to [...]

Published
2023

3. Trevena Announces Completion of Initial Analysis of OLINVYK Continuous Respiratory Monitoring Data

Subjects
Trevena Inc., Medical research, Medicine, Experimental, Nervous system diseases, Pharmaceutical industry, General interest, News, opinion and commentary, Olinvyk (Medication)
Abstract

CHESTERBROOK: Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced completion of initial analysis of OLINVYK continuous [...]

Published
2023

4. Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

Subjects
Trevena Inc., Opioids, Neonatology, Pharmaceutical industry, Banking, finance and accounting industries, Olinvyk (Medication)
Abstract

(GlobeNewswire) - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced receipt of [...]

Published
2023

5. Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

Subjects
Trevena Inc., Medical research, Medicine, Experimental, Medical societies, Neonatology, Nalbuphine, Type 2 diabetes, Pharmaceutical industry, Banking, finance and accounting industries, Business, Olinvyk (Medication)
Abstract

$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China New OLINVYK respiratory data from VOLITION ~200 patient real-world [...]

Published
2023

6. Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones

Subjects
Trevena Inc., The NASDAQ Stock Market L.L.C., Financial markets, Neonatology, Securities industry, Pharmaceutical industry, Securities industry, Banking, finance and accounting industries, Olinvyk (Medication)
Abstract

(GlobeNewswire) - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it [...]

Published
2023

7. Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones

Subjects
Trevena Inc., The NASDAQ Stock Market L.L.C., Financial markets, Neonatology, Nalbuphine, Securities industry, Pharmaceutical industry, Securities industry, Banking, finance and accounting industries, Business, Olinvyk (Medication)
Abstract

CHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system [...]

Published
2023

8. Trevena Announces Approval of OLINVYK in China

Subjects
Trevena Inc., Pharmaceutical industry, General interest, News, opinion and commentary, Olinvyk (Medication)
Abstract

CHESTERBROOK: Trevena, Inc. has issued the following news release: Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous [...]

Published
2023

9. Trevena Announces Approval of OLINVYK in China

Subjects
Trevena Inc., Neonatology, Nalbuphine, Pharmaceutical industry, Banking, finance and accounting industries, Business, Olinvyk (Medication)
Abstract

Trevena's partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangsu Nhwa Additional $15 million to Trevena expected on [...]

Published
2023

10. Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study

Subjects
Trevena Inc., Medical research, Medicine, Experimental, Neonatology, Nalbuphine, Pharmaceutical industry, Banking, finance and accounting industries, Business, Olinvyk (Medication)
Abstract

OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on initial EMR [...]

Published
2023

11. Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings

Subjects
Trevena Inc., Seizures (Medicine), Neonatology, Nalbuphine, Pharmaceutical industry, Banking, finance and accounting industries, Business, Olinvyk (Medication)
Abstract

TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual Meeting OLINVYK poster presentation on reduced effect on neurocognitive function [...]

Published
2022

12. Trevena Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) - Final

Subjects
Oppenheimer and Company Inc., Trevena Inc., Insurance industry, Securities industry, Pharmaceutical industry, Securities industry, Insurance industry, Business, Olinvyk (Medication)
Abstract

Presentation JEFF JONES, ANALYST, OPPENHEIMER & CO. INC.: Thank you, everyone, and welcome to day 2 of Oppenheimer's Fall Healthcare and Life Sciences Summit. This is Jeff Jones. I am [...]

Published
2021

13. Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update

Subjects
Trevena Inc., Morphine, Group purchasing organizations, Neonatology, Pharmaceutical industry, Banking, finance and accounting industries, Business, Olinvyk (Medication)
Abstract

CHESTERBROOK, Jul 28, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:TRVN), EQNX::TICKER_END OLINVYK demonstrated statistically significant reduced impact on neurocognitive functioning vs IV morphine on primary endpoint Successfully negotiated OLINVYK [...]

Published
2022

14. Jiangsu Nhwa Pharmaceutical, a Trevena partner, has submitted a New Drug Application in China for OLINVYK(r)

Subjects
United States. Food and Drug Administration, Trevena Inc., Drug approval, Pharmaceutical industry, General interest, News, opinion and commentary, Olinvyk (Medication)
Abstract

CHESTERBROOK, Pa: Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that China's National Medical [...]

Published
2022

16. Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team

Subjects
Trevena Inc., Biological products industry, Pharmaceutical industry, Banking, finance and accounting industries, Business, Olinvyk (Medication)
Abstract

CHESTERBROOK, Pa., Nov 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central [...]

Published
2021

17. Trevena Announces Two OLINVYK(R) Presentations at ANESTHESIOLOGY(R) 2021

Subjects
Trevena Inc., Executives, Medical societies, Database industry, Pharmaceutical industry, Database industry, Banking, finance and accounting industries, Business, Olinvyk (Medication)
Abstract

CHESTERBROOK, Pa., Oct 13, 2021 (GLOBE NEWSWIRE via COMTEX) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central [...]

Published
2021

18. Trevena Announces Two OLINVYKA Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGYA 2021

Subjects
Trevena Inc., Executives, Medical societies, Pharmaceutical industry, Telecommunications industry, Olinvyk (Medication)
Abstract

(GlobeNewswire) - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the acceptance [...]

Published
2021

19. Trevena Announces Two OLINVYK Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY 2021

Subjects
Trevena Inc., Executives, Medical societies, Pharmaceutical industry, Business, international, Law, Olinvyk (Medication)
Abstract

(GlobeNewswire) - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the acceptance [...]

Published
2021

21. Trevena Announces Wake Forest Baptist Health Joining OLINVYK Clinical Outcomes Study

Subjects
Trevena Inc., Pharmaceutical industry, Business, international, Law, Olinvyk (Medication)
Abstract

(GlobeNewswire) - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced Wake Forest [...]

Published
2021

22. Trevena Announces Wake Forest Baptist Health Joining OLINVYK(R) Clinical Outcomes Study

Subjects
Trevena Inc., Pharmaceutical industry, Banking, finance and accounting industries, Business, Olinvyk (Medication)
Abstract

CHESTERBROOK, Pa., Aug 25, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Study is being led by Cleveland Clinic; designed to evaluate potential benefit of OLINVYK on respiratory, GI, and cognitive [...]

Published
2021

23. Trevena Announces Wake Forest Baptist Health Joining OLINVYK(r) Clinical Outcomes Study

Subjects
Trevena Inc., Pharmaceutical industry, General interest, News, opinion and commentary, Olinvyk (Medication)
Abstract

Chesterbrook: Trevena, Inc. (TRVN) has issued the following press release: Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central [...]

Published
2021

26. Trevena publishes analysis of OLINVYK in pain and therapy

Subjects
Trevena Inc., Nervous system diseases -- Care and treatment, Pharmaceutical industry, General interest, News, opinion and commentary, Olinvyk (Medication)
Abstract

CHESTERBROOK, Pa.: Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced the publication of an exploratory analysis [...]

Published
2021

27. Trevena Announces Presentation of OLINVYK(R) Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting

Subjects
Trevena Inc., Conferences and conventions, Analgesics, Pharmaceutical industry, Banking, finance and accounting industries, Business, Olinvyk (Medication)
Abstract

CHESTERBROOK, May 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Elderly and obese patients receiving OLINVYK are not at increased risk for respiratory depression, compared to younger and non-obese patients, [...]

Published
2021

28. Trevena, Inc. Announces Publication Highlighting OLINVYK Respiratory Safety Data in High-Risk Patients in Pain & Therapy

Subjects
Trevena Inc., College teachers, Body mass index, Pharmaceutical industry, Business, international, Law, Olinvyk (Medication)
Abstract

(GlobeNewswire) - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication [...]

Published
2021

29. Trevena, Inc. Announces Publication Highlighting OLINVYK(TM) Respiratory Safety Data in High-Risk Patients in Pain & Therapy

Subjects
Trevena Inc., Drugs, Body mass index, Pharmaceutical industry, Banking, finance and accounting industries, Business, Olinvyk (Medication)
Abstract

CHESTERBROOK, Pa., Jan 28, 2021 (GLOBE NEWSWIRE via COMTEX) -- -- Low incidence of respiratory depression observed with OLINVYK (oliceridine) injection regardless of age or body mass index, in exploratory [...]

Published
2021

30. Trevena, Inc. Announces DEA Scheduling of OLINVYK (oliceridine) injection

Subjects
United States. Drug Enforcement Administration, Trevena Inc., Tapentadol, Pharmaceutical industry, Drug approval, Business, international, Law, Olinvyk (Medication)
Abstract

(GlobeNewswire) - Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that oliceridine [...]

Published
2020

31. Oliceridine (Olinvyk) Offers New Treatment Option for Acute Pain Management in Hospitals and Controlled Clinical Settings

Author

Leszcynski, Leah C. and Chamberlin, Kevin W.

Subjects
Trevena Inc., Opioids, Pain -- Care and treatment, Pharmaceutical industry, Business, Pharmaceuticals and cosmetics industries, Olinvyk (Medication)
Abstract

Oliceridine (Olinvyk; Trevena, Inc) is an intravenous (IV) opioid agonist indicated in adults for management of acute severe pain in a hospital or controlled clinical setting. (1,2) Oliceridine should only [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results